Synopsis Outlining how 3D cell culturing allows for efficient, controlled production of allogeneic cell therapy products How PLX technology creates competitive advantage Creating an in-house CMC facility to allow for seamless scale up
12.30 Discuss: What are the Various Manufacturing Business Models that can be Applied to Successfully Meet Patient Demand?
Designing manufacturing facilities that meet GMP guidelines can be a slow and expensive venture therefore, future strategies must be robust whilst maintain flexibility, discuss the various approaches that can be taken to ensure this.
What ever happened to offering options for incentive? I guess they got sick of them expiring below excercise price, so they decided to just give themselves an absurd amount of free ones. Looking around other small cap Biotechs, options seemed to be the norm. I am astonished by the size of these shares that the board decided to give. They also snuck in 278,000 for Egozi as well.
" We did not conduct any analysis of salaries and monthly compensation received by our named executive officers' respective counterparts in companies in the biotechnology industry and other comparable companies in Israel in the fiscal year ended June 30, 2015 and Fiscal 2016"
Now that's what a good BOD should do eh?
The two clowns on top also get 1.5% and 1% bonus for any non-dilutive funding they receive. So every grant they get a nice little chunk of cash. Whatever happened to just working for a company for the benefit of the company. Not everything needs to be a bonus.
Zami is building up a nice nestegg if he was to get terminated. It's been building since at least 2011. His monthly consulting fee is $31,250.
"In addition, in the event of termination of our co-CEO, Mr. Aberman's, consulting agreement, he will be entitled to receive an adjustment fee that equals the monthly consulting fees multiplied by 3 plus the number of years the Consulting Agreement is in force from the second year, but in any event no more than nine years in the aggregate. Our co-CEO, Mr. Yanay, may be entitled to a severance payment that equals a month's compensation for each twelve-month period of employment or otherwise providing services to the Company."
If nothing MAJOR happens in the next week or two MAX, this company is pure garbage for what they did. Only people not making money are any investors. Sick of this company and sick of this price. Hopefully my views change soon, but I'm not holding my breath.
And we wonder why institutional numbers don't really change from their pathetic percentages...
Cell therapy - the next generation of biological therapeutic products - Pluristem Therapeutics Inc.
the Board agreed to issue Mr. Yanay a restricted stock grant of an aggregate of 2,000,000 shares . I first read his salary and said not so bad but am I reading how much stock these guys just gave themselves?
Japan's Laws Supporting Accelerated Pathways for Cell Therapies | BioInformant
In late 2014, Japan passed two new laws that revolutionized the commercialization of cell therapies within the country by providing an accelerated pathway for product approvals. While there has been much discussion about these laws, few people have a
PLX is PSTI? what would you pick? both Israel based and similar market caps. imo PLX with it's ProCellex platform proved already they can deliver superior cell plant ERTs by having Elelyso approved in 2012. Fabry and CF data in the current pipeline looks very good. Potential is huge just patience.
Next Tuesday ! Get Ready....For...Breakout...Betty ! Are..You....Ready...Teddy ?
Join the leaders and pioneers in a collaborative platform to ensure novel cell therapies are delivered to patients at scale & commercialized
Neupogen vs PLX R18
In searching for study results for Neupogen, I found an incredibly interesting tidbit. In their study from 2013, they used only male NHP's
"Study AXR01 (35) was conducted to define a rhesus macaque model of H-ARS. This well-characterized model of H-ARS would be used to assess the efficacy of drug products proposed for the treatment of H-ARS. Forty-eight male rhesus macaques (Macaca mulatta) were exposed to 6 MV of bilateral, TBI administered by a photon linear accelerator (LINAC)."
We had 100% survival rate in males with the 2 lower doses. So what would Neupogen's survival rate have been if it included females in the study? How did they not include females? Why did Pluristem's include both and not theirs? Could you imagine the difference in our price right now if we showed 100% survival. This now becomes an unfair comparison between the two. ARRRGGHHHHH!!!
Food For Thought !
It Just Occurred To Me After Re-Reading The Actions Of The Board of Directors Both In March..2-CEO's.. And Now In June... On The Surface At Least, It Appears They May Be Preparing To Split The Company Into 2 Separate Units ?
IMO..If That Is In Fact What They Are Planning ? I Would Guess They Would Make PLX-R18 As One Stand Alone Entity & PLX-PAD As Another ?
Sounds Wild, But It May Make Good Logistical Business Sense As Each Product Does Have Indications In Large Markets And Besides Any Company With Future Takeover Plans Would Have To Take-Over 2 Companies !
Does Anyone Else Think This Is A Possibility ? If They Are Laying The Goundwork For Such A Move, We Long Shareholders Would Own Equal Shares In Both Companies... To That I Would Say: GIDDY-UP !
Check This Out ! You Can Bet Pluristem Was At This Meeting This Past Monday IMO !
U.S. Department of Defense Officials Introduce New Strategies to Stimulate Medical Countermeasures Development
For the past several years, BIO has had the opportunity to partner with the U.S. Department of Defense (DoD) during the annual BIO International Convention to provide an open forum to discuss the c…
Hey 1stock. You were showing Neupogen's ARS study had 79%/41% survival to placebo. Edison report is showing 79%/59%. Where did you get these results. I was looking around and did find some things on Neupogens trials, and some/most primates also needed blood transfusions and antibiotics. Edison's numbers give us a better rate, and would just like to find something myself. Seeing different numbers from a few different sources, so I don't know what to think.
GIDDY-UP ! From Edison Research Report !
ARS would qualify for a priority review voucher.
The legislation regarding the award of priority review vouchers (PRVs) was expanded under the 21st Century Cures Act to include products that address a threat to national security. PLX-R18 should therefore be eligible for such a voucher. The most recent sale of a PRV was for $125m (from Sarepta to Gilead in February 2017), although we expect these prices to drop with the expansion of the program.
Seems like they have been playing with government money for a long time.
Positive trends in radiation treatment | Pluristem Therapeutics
Pluristem reported data from its pilot study of PLX-R18 for the treatment of acute radiation syndrome (ARS). The study included 48 non-human primates (NHP) who were dosed with 4m, 10m, and 20m cells per kg and showed an improvement in survival to 83%
I think bluehorses hit the mark on where a lot of people are at. At least with this: "their reputation is at stake as a company." More specificially that "they put the guidance out for 2017 and if they don't hit the marks, you can buy this stock for pennies and they should be voted out." I am not yet as critical of the dual-CEO idea or of Yaky and Zami as some of you guys are, but this year has been built up with expectations by them, and if they don't deliver, it should be them on the chopping blocks. I can understand the China deal not going through for the moment, only because there is a lot of blossoming and changes going on in that country to the point where I can see why a deal might need to be scrapped and started over from the beginning. I'm not an expert, it just seems like something that wouldn't be hard to imagine. As for the Sosei deal, I have no idea. That's already been delayed but apparently they are expecting it to be hammered out in Q3/2017? The big whopper to me will be what the United States decides to do going forward. If we can get a contract that will pay our bills for the next 3-5 years, I think this stock would move big time. Or maybe on a longer shot, if something incredible came out of Fukushima or the NY Blood Center. Still a lot to wait for this year and we should at least give the benefit of the doubt for the rest of the year, IMHO, before we break out the pitchforks. They do have 3 Phase III trials about to start, and cruising between $1.25-$1.50 seems low to me for a company with this far advanced trials, US gov't sponsorship, patented manufacturing processes, and with such good trial results in every indication they've touched so far. I don't know whats going on with the partnerships, if it is a problem with the CEOs, but we have great products with only a couple years needed for approval, IMHO. Reassessing my position and commitment to this company at the end of December. Have shares and options. Been long for 7 years at least, in case you were wondering.
It's been a while since I've been around here, but I see Allo is still up to the same nonsense from 6 years ago. Funny how nothing changes on this board and nothing changes with the company. Zami & Yaky, and Allo all need to go.
With partners dropping out there is something going on...there either making a big deal with only one merger or the ARS product buyer wants control as a national security issue..
Pluristem Therapeutics Inc. NASDAQ $PSTI Correlation Histogram
X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks Sep-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is 0.3 In other words, the correlation coefficient of the other stock
Regulatory Explainer: Everything You Need to Know About FDA’s Priority Review Vouchers
Since 2007, the US Food and Drug Administration (FDA) has issued a handful of special "priority review" vouchers which allow its recipient to expedite the review of any one of its new drug products. What are these vouchers, why is FDA issuing them an